Links of the day: Biopharma has abandoned antibiotic development. Here’s why we did, too.
Recently, I wrote a piece arguing that pharma companies should be paid directly by the state for developing new drugs (really, they should). This article provides a more in-depth view into why so many pharma companies have abandoned developing antibiotics. Spoiler: It is currently almost impossible to make a profit of it.